Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.59 |
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.41 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.38 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | MC4R | P32245 | 1/20 | 0.59 |
| ▸ | MC3R | P41968 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7668906 | 1.00 | BAZ2B (0.59) | BAZ2BADORA3TSHRMC4RADRA1A | |
| SCHEMBL1442775 | 0.98 | — | — | |
| Pyrazinamide SCHEMBL27524986 | 0.77 | ADORA3 (0.95) | BAZ2BADORA3TSHRMC4RADRA1A | |
| Pyrazinamide SCHEMBL6162016 | 0.77 | ADORA3 (0.95) | BAZ2BADORA3TSHRMC4RADRA1A | |
| Pyrazinamide SCHEMBL5010455 | 0.77 | ADORA3 (0.95) | BAZ2BADORA3TSHRMC4RADRA1A | |
| Pyrazinamide SCHEMBL27474998 | 0.77 | ADORA3 (0.95) | BAZ2BADORA3TSHRMC4RADRA1A | |
| Pyrazinamide SCHEMBL32667957 | 0.77 | ADORA3 (0.95) | BAZ2BADORA3TSHRMC4RADRA1A | |
| Pyrazinoic Acid SCHEMBL27366253 | 0.77 | KDM4E (0.80) | BAZ2BADORA3TSHRMC4RADRA1A | |
| SCHEMBL4904135 | 0.76 | BAZ2B (0.52) | BAZ2BADORA3TSHRMC4RADRA1A | |
| Pyrazinamide SCHEMBL11616580 | 0.76 | ADORA3 (0.91) | BAZ2BADORA3TSHRMC4RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119674190-A | Organic-inorganic composite polymer solid electrolyte and preparation method and application thereof | 山东创鲁先进电池科技有限公司 | 2025-03-21 | — | — | CN | claimed |
| EP-1891052-A1 | TUBULIN INHIBITOR AND PROCESS FOR ITS PREPARATION | Wyeth (US) | 2008-02-27 | — | — | EP | claimed |
| US-7244736-B2 | Tubulin inhibitor and process for its preparation | WYETH (US) | 2007-07-17 | — | — | US | claimed |
| WO-2006138180-A1 | TUBULIN INHIBITOR AND PROCESS FOR ITS PREPARATION | WYETH (US) | 2006-12-28 | — | — | WO | claimed |
| US-20060281760-A1 | Tubulin inhibitor and process for its preparation | WYETH (US) | 2006-12-14 | — | — | US | claimed |
| EP-3892617-B1 | FLUORINATED PYRIMIDINE COMPOUND AND PRODUCTION METHOD THEREFOR | UNIMATEC CO LTD (JP) | 2025-04-30 | — | — | EP | disclosed |
| CN-119674190-A | Organic-inorganic composite polymer solid electrolyte and preparation method and application thereof | 山东创鲁先进电池科技有限公司 | 2025-03-21 | — | — | CN | disclosed |
| US-12043615-B2 | Fluorine-containing pyrimidine compound and method for manufacturing the same | UNIMATEC CO., LTD. (JP) | 2024-07-23 | — | — | US | disclosed |
| CN-118005564-A | 4' -O-methyl psoralea chalcone analogue, preparation method, preparation intermediate and application thereof | 重庆医科大学 | 2024-05-10 | — | — | CN | disclosed |
| US-11946198-B2 | Disperse azo dyes, a process for the preparation thereof and the use thereof | HUNTSMAN TEXTILE EFFECTS (SWITZERLAND) GMBH (CH) | 2024-04-02 | — | — | US | disclosed |
| CN-114929809-B | Disperse azo dyes, process for their preparation and their use | 亨斯迈纺织染化(瑞士)有限公司 | 2023-12-15 | — | — | CN | disclosed |
| EP-4090709-B1 | DISPERSE AZO DYES, A PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF | HUNTSMAN TEXTILE EFFECTS SWITZERLAND GMBH (CH) | 2023-11-29 | — | — | EP | disclosed |
| WO-2002024665-A1 | ARYLALKANE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | ACTELION PHARMACEUTICALS LTD (CH) | 2002-03-28 | — | — | WO | disclosed |
| WO-2002008200-A2 | ARYLETHENE-SULFONAMIDES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2002-01-31 | — | — | WO | disclosed |
| US-20020004600-A1 | Process for the preparation of substituted pyrimidines | AMERICAN CYANAMID COMPANY | 2002-01-10 | — | — | US | disclosed |
| US-6281358-B1 | REACTING AN AMIDINE COMPOUND WITH A VINYLCARBONYL COMPOUNDIN INERT SOLVENT IN PRESENCE OF BASE | AMERICAN CYANAMID COMPANY | 2001-08-28 | — | — | US | disclosed |
| WO-2001042242-A1 | ANTIBACTERIAL HETEROBICYCLIC SUBSTITUTED PHENYL OXAZOLIDINONES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-06-14 | — | — | WO | disclosed |
| CN-1290270-A | Streptogramin derivatives, preparation method and compositions containing them | AWENTIS PHARMACEUTICS S A (FR) | 2001-04-04 | — | — | CN | disclosed |
| WO-2000063183-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRIMIDINES | AMERICAN CYANAMID COMPANY (US) | 2000-10-26 | — | — | WO | disclosed |
| EP-0455356-A1 | Substituted 5-amino-1,2,4-thiadiazoles with pharmaceutical activity | LILLY INDUSTRIES LIMITED (GB) | 1991-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12043615-B2 | Fluorine-containing pyrimidine compound and method for manufacturing the same | CNOT1, NUDT1, XRN2 | ADRA1A 372/4885HSP90AA1 2096/4885HDAC3 3048/4885 |
| US-20060281760-A1 | Tubulin inhibitor and process for its preparation | TUBB1, TUBB6, TUBB | ADRA1A 2777/4885HSP90AA1 441/4885HDAC3 1798/4885 |
| US-20020004600-A1 | Process for the preparation of substituted pyrimidines | XRN2, HPRT1, POLR2H | ADRA1A 2174/4885HSP90AA1 4476/4885HDAC3 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.